Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
| Company | Current Parent | Current Parent Industry  | Primary Offense Type | Year | Agency | Penalty Amount |
|---|---|---|---|---|---|---|
| Merck | Merck | pharmaceuticals | environmental violation | 2011 | EPA | $1,500,000 |
| Advanced Sterilization Products, a division of Ethicon Inc. | Johnson & Johnson | pharmaceuticals | drug or medical equipment safety violation | 2013 | FDA | $1,200,000 |
| Teva Pharmaceuticals USA Inc. | Teva Pharmaceutical Industries | pharmaceuticals | environmental violation | 2013 | EPA | $2,250,000 |
| Genzyme Corporation | Sanofi | pharmaceuticals | drug or medical equipment safety violation | 2015 | FDA | $32,587,439 |
| Endo Health Solutions Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
| Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
| Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | drug or medical equipment safety violation | 2012 | FDA | $55,000,000 |
| Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Cypress Pharmaceutical Inc. | Currax Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $2,800,000 |
| Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
| Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
| UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
| Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Advanced Sterilization Products | Johnson & Johnson | pharmaceuticals | environmental violation | 2014 | EPA | $136,800 |
| Pfizer Pharmaceuticals LLC | Pfizer | pharmaceuticals | environmental violation | 2014 | EPA | $728,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| St. Jude Medical Inc. | Abbott Laboratories | pharmaceuticals | kickbacks and bribery | 2011 | DOJ_CIVIL | $16,000,000 |
| Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | FDA | $41,500,000 |
| Novartis Pharmaceuticals | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| Phibrochem, Inc. | Phibro Animal Health | pharmaceuticals | export control violation | 2012 | BIS | $31,000 |
| Acclarent Inc. | Johnson & Johnson | pharmaceuticals | False Claims Act and related | 2016 | DOJ_CIVIL | $18,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2016 | DOJ_CIVIL | $784,600,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | DOJ_CIVIL | $46,500,000 |
| Cephalon Inc. | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2015 | DOJ_CIVIL | $7,500,000 |
| Genzyme Corp. | Sanofi | pharmaceuticals | False Claims Act and related | 2013 | DOJ_CIVIL | $22,280,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
| St. Jude Medical Inc. | Abbott Laboratories | pharmaceuticals | False Claims Act and related | 2012 | DOJ_CIVIL | $3,650,000 |
| Dava Pharmaceuticals Inc. | Endo International | pharmaceuticals | False Claims Act and related | 2012 | DOJ_CIVIL | $11,000,000 |
| Dey Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Roxane Laboratories Inc. | Hikma Pharmaceuticals | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Abbott Laboratories Inc. | AbbVie | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $126,500,000 |
| Eon Labs Inc. | Novartis | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $3,500,000 |
| Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
| Sandoz, Inc. | Sandoz Group | pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $12,640,000 |
| Sandoz, Inc. | Sandoz Group | pharmaceuticals | HHS civil monetary penalties | 2011 | HHSOIG | $230,000 |
| EMD Chemicals, Inc. | Merck KGaA (EMD) | pharmaceuticals | export control violation | 2007 | BIS | $44,000 |
| CAMBRIDGE MAJOR LABORATORIES INC | Alcami | pharmaceuticals | motor vehicle safety violation | 2006 | FMCSA | $18,560 |
| EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | pharmaceuticals | motor vehicle safety violation | 2006 | FMCSA | $7,614 |
| CAMBRIDGE MAJOR LABORATORIES INC | Alcami | pharmaceuticals | motor vehicle safety violation | 2005 | FMCSA | $15,820 |
| EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | pharmaceuticals | motor vehicle safety violation | 2004 | FMCSA | $13,170 |
| PHIBRO-TECH, INC. | Phibro Animal Health | pharmaceuticals | railroad safety violation | 2008 | FRA | $5,650 |
| Mylan Laboratories, Inc. | Viatris | pharmaceuticals | consumer protection violation | 2000 | FTC | $100,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | drug or medical equipment safety violation | 2007 | DOJ_ANTITRUST | $1,000,000 |
| Hoechst AG | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | DOJ_ANTITRUST | $12,000,000 |
| Merck KgaA | Merck KGaA (EMD) | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | DOJ_ANTITRUST | $14,000,000 |
| AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $2,600,000 |
| Mylan Pharmaceuticals and UDL Laboratories | Viatris | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $118,000,000 |
| Ortho McNeil Pharmaceutical | Johnson & Johnson | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $3,400,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Aventis Pharmaceutical Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $95,500,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| King Pharmaceuticals | Pfizer | pharmaceuticals | False Claims Act and related | 2005 | DOJ_CIVIL | $124,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2005 | DOJ_CIVIL | $150,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
| Pfizer Corporation | Pfizer | pharmaceuticals | False Claims Act and related | 2002 | DOJ_CIVIL | $49,000,000 |
| Johnson & Johnson Medical, Inc. | Johnson & Johnson | pharmaceuticals | False Claims Act and related | 2001 | DOJ_CIVIL | $3,900,000 |
| Novo Nordisk A/S | Novo Holdings A/S | pharmaceuticals | kickbacks and bribery | 2009 | DOJ_CRIMINAL | $9,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
| Merck | Merck | pharmaceuticals | environmental violation | 2007 | EPA | $19,750,000 |
| Mallinckrodt, Inc. | Mallinckrodt | pharmaceuticals | nuclear safety violation | 2000 | NRC | $125,000 |
| EMD Chemicals, Inc. | Merck KGaA (EMD) | pharmaceuticals | economic sanction violation | 2007 | OFAC | $8,250 |
| Chiron Corporation Ltd | Novartis | pharmaceuticals | economic sanction violation | 2004 | OFAC | $168,500 |
| DuPont Pharmaceuticals Company | Bristol-Myers Squibb | pharmaceuticals | economic sanction violation | 2004 | OFAC | $6,600 |
| Fort Dodge Animal Health | Zoetis | pharmaceuticals | economic sanction violation | 2004 | OFAC | $26,956 |
| ICN Pharmaceuticals, Inc | Bausch Health | pharmaceuticals | economic sanction violation | 2004 | OFAC | $5,500 |
| Biovail Corporation | Bausch Health | pharmaceuticals | accounting fraud or deficiencies | 2008 | SEC | $10,000,000 |
| Elan Corporation, plc | Perrigo | pharmaceuticals | accounting fraud or deficiencies | 2005 | SEC | $15,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | investor protection violation | 2003 | SEC | $1,000,000 |
| ICN Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | accounting fraud or deficiencies | 2002 | SEC | $1,000,000 |
| GNC Holdings Inc. | Harbin Pharmaceutical Group | pharmaceuticals | drug or medical equipment safety violation | 2016 | FDA | $2,250,000 |
| AstraZeneca PLC | AstraZeneca | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $5,522,000 |
| GlaxoSmithKline plc | GlaxoSmithKline | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $20,000,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | investor protection violation | 2017 | SEC | $15,000,000 |
| Amneal Pharmaceuticals of NY, LLC | Amneal Pharmaceuticals | pharmaceuticals | employment discrimination | 2015 | OFCCP | $99,000 |
| Novartis Pharmaceuticals | Novartis | pharmaceuticals | employment discrimination | 2013 | OFCCP | $51,594 |
| VALEANT PHARMACEUTICALS INTERNATIONAL, INC. | Bausch Health | pharmaceuticals | benefit plan administrator violation | 2016 | EBSA | $10,001 |
| BIOVAIL AMERICAS CORP. | Bausch Health | pharmaceuticals | benefit plan administrator violation | 2012 | EBSA | $10,001 |
| CHEROKEE PHARMACEUTICALS LLC | Merck | pharmaceuticals | benefit plan administrator violation | 2011 | EBSA | $10,001 |
| NOVARTIS PHARMACEUTICALS CORPORATION | Novartis | pharmaceuticals | benefit plan administrator violation | 2006 | EBSA | $10,001 |
| IMMUNOMEDICS, INC. EMPLOYEES' 401(K) SAVINGS PLAN | Gilead Sciences | pharmaceuticals | benefit plan administrator violation | 2001 | EBSA | $10,001 |
| InterMune Inc. | Roche | pharmaceuticals | Family and Medical Leave Act | 2014 | WHD | $59,085 |
| Perrigo Company | Perrigo | pharmaceuticals | Family and Medical Leave Act | 2014 | WHD | $15,022 |
| Schering Corporation | Merck | pharmaceuticals | Family and Medical Leave Act | 2006 | WHD | $6,000 |
| EMD Millipore Corp. | Merck KGaA (EMD) | pharmaceuticals | environmental violation | 2017 | EPA | $385,000 |
| Parexel International, LLC | Parexel International | pharmaceuticals | labor relations violation | 2012 | NLRB | $253,000 |
| Amgen, Inc. | Amgen | pharmaceuticals | labor relations violation | 2011 | NLRB | $40,000 |
| Merck and Company, Inc. | Merck | pharmaceuticals | labor relations violation | 2009 | NLRB | $10,710 |
| Merck & Co., Inc. | Merck | pharmaceuticals | labor relations violation | 2008 | NLRB | $100,000 |
| Schering-Plough | Merck | pharmaceuticals | labor relations violation | 2007 | NLRB | $8,200 |
| Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | pharmaceuticals | labor relations violation | 2004 | NLRB | $50,000 |
| Advanced Medical Optics | Abbott Laboratories | pharmaceuticals | labor relations violation | 2004 | NLRB | $16,800 |
